Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

OS Therapies Incorporated Common Stock (NY:OSTX)

1.215 +0.035 (+2.97%)

Streaming Delayed Price Updated: 3:01 PM EST, Feb 23, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	267,984
Open	1.190
Bid (Size)	1.210 (300)
Ask (Size)	1.220 (200)
Prev. Close	1.180
Today's Range	1.185 - 1.225
52wk Range	1.120 - 2.570
Shares Outstanding	5,847,955
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

OS Therapies Provides Global Regulatory Update for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metstatic Osteosarcoma ↗

February 17, 2026

Additional forthcoming biomarker data from human trial expected to further characterize immune pathway activation and its relationship to clinical outcomesU.S.,...

Via Newsfile

OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma Immunotherapies

February 04, 2026

New York, New York--(Newsfile Corp. - February 4, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or...

Via Newsfile

Performance

YTD	-9.3%	-9.3%
1 Month	-17.3%	-17.3%
3 Month	-29.4%	-29.4%
6 Month	-44.5%	-44.5%
1 Year	-28.5%	-28.5%

More News

OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

February 02, 2026

Via Newsfile

OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

January 15, 2026

Via Newsfile

OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary

January 14, 2026

Via Newsfile

OS Therapies Enters into Warrant Inducement Agreements

January 12, 2026

Via Newsfile

OS Therapies Provides First Half 2026 Corporate Outlook

January 05, 2026

Via Newsfile

Market Signals Highlight Next Wave of Immunotherapy Growth (OSTX, IBRX)

December 16, 2025

Via AB Newswire

OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

December 15, 2025

Via Newsfile

OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

December 09, 2025

Via Newsfile

OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility

December 05, 2025

Via Newsfile

OS Therapies Receives Non-Proprietary Name 'daznelimgene lisbac' for OST-HER2 from World Health Organization

November 25, 2025

Via Newsfile

Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) 3Q25

November 21, 2025

Via Newsfile

OS Therapies to Spinoff OS Animal Health into Standalone Public Company

November 20, 2025

Via Newsfile

OS Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update

November 17, 2025

Via Newsfile

Why Quantum Computing Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket ↗

November 17, 2025

Via Benzinga

OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

October 22, 2025

Via Newsfile

OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

October 17, 2025

Via Newsfile

OS Therapies Reports Strong 2-Year Survival Data For Bone Cancer Immunotherapy Candidate ↗

October 10, 2025

Via Benzinga

OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma

October 10, 2025

Via Newsfile

OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting

October 09, 2025

Via Newsfile

OS Therapies to Participate in Fall 2025 Conferences and Events

October 07, 2025

Via Newsfile

OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update

September 30, 2025

Via Newsfile

OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT

September 19, 2025

Via Newsfile

OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit

September 12, 2025

Via Newsfile

Frequently Asked Questions

Is OS Therapies Incorporated Common Stock publicly traded?

Yes, OS Therapies Incorporated Common Stock is publicly traded.

What exchange does OS Therapies Incorporated Common Stock trade on?

OS Therapies Incorporated Common Stock trades on the New York Stock Exchange

What is the ticker symbol for OS Therapies Incorporated Common Stock?

The ticker symbol for OS Therapies Incorporated Common Stock is OSTX on the New York Stock Exchange

What is the current price of OS Therapies Incorporated Common Stock?

The current price of OS Therapies Incorporated Common Stock is 1.215

When was OS Therapies Incorporated Common Stock last traded?

The last trade of OS Therapies Incorporated Common Stock was at 02/23/26 03:01 PM ET

What is the market capitalization of OS Therapies Incorporated Common Stock?

The market capitalization of OS Therapies Incorporated Common Stock is 7.11M

How many shares of OS Therapies Incorporated Common Stock are outstanding?

OS Therapies Incorporated Common Stock has 7M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.